This is an auto-generated stub page built from atlas entry frontmatter. A richer
hand-crafted page is planned. See the
atlas source
for the full entry including detailed body sections.
angiopoietin
Angiopoietin
Angiopoietins (Ang-1, Ang-2) bind Tie2 on endothelium; Ang-1 stabilizes vessels; Ang-2 destabilizes and cooperates with VEGF for angiogenesis and vascular leak. Faricimab (anti-Ang-2/VEGF-A bispecific) treats diabetic macular edema and nAMD with extended Q16W dosing intervals.
Entry Metadata
| Field | Value |
|---|---|
| ID | angiopoietin |
| Name | Angiopoietin |
| Status | draft |
| Last reviewed | 2026-06-07 |
| Atlas | 01-human |
| Scale | 03-molecular |
Cross-Atlas Connections
Sources
- Davis S, Aldrich TH, Jones PF, et al. Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning. Cell. 1996;87(7):1161-1169. · PubMed 8980223
- Maisonpierre PC, Suri C, Jones PF, et al. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science. 1997;277(5322):55-60. · PubMed 9204896
- Wykoff CC, Abreu F, Adamis AP, et al. Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials. Lancet. 2022;399(10326):741-755. · PubMed 35085503